NEW YORK (GenomeWeb News) – NextBio today announced it has forged a multiyear deal with Sanofi for use of the NextBio Clinical platform in the drug manufacturer's R&D work.
Sanofi will use the platform for aggregating, standardizing, and analyzing patient clinical data, next generation sequencing, and other molecular data across public data sources, Sanofi's clinical trials, and Sanofi's hospital partners, NextBio said. Sanofi is using the NextBio Clinical platform as part of its Translational Medicine for Patients program.
NextBio said that the system will allow Sanofi to leverage a vast and growing pool of patient data for translational and clinical research.
"The new translational medicine partnership with NextBio, with its big data genomics capabilities, will enable Sanofi to implement patient-centered approaches across all stages of translational and clinical research in several major therapeutic areas, including oncology and diabetes," NextBio President and CEO Saeid Akhtari said in a statement.
Financial and other terms of the deal were not disclosed.